SOFI offers a refreshing change to the bead-based immunoassay. The microsphere-based multiplexed immunoassay format offers high sensitivity and good flexibility for development of new assays. While this assay format has seen widespread adoption in many life science research applications, market penetration in high-throughput labs is limited by low assay read speed, high reagent costs, and inadequate instrument reliability.
SOFI offers higher sensitivity than traditional bead-based assay platforms combined with multiplexing up to 50 target analytes. Our scanning technology delivers read times of less than 15 minutes for 96-well plates, and the elimination of read failures associated with sample handling that are prevalent in flow cytometer-based assay readers.
SOFI is an open platform, meaning that you have instant access to many of the commercially-available assay kits already on the market.
Running CBA multiplexed assays on SOFI offers flexibility, speed and sensitivity on a no-hassle benchtop platform.